Selective dopamine neurotoxicity by an industrial chemical: An environmental cause of Parkinson's disease?

Brain Research

Volumn 774, Issue 1-2, 1997, Pages 260-264

  Masalha, Rafik ^a   Herishanu, Yuval ^a   Alfahel Kakunda, Angel ^a   Silverman, William F ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Anti oxidant; Catecholamine; Hindered amine; Parkinson's disease; Substantia nigra

Indexed keywords

DITHIOCARBAMIC ACID DERIVATIVE; DOPAMINE; DROMETRIZOLE; INDUSTRIAL CHEMICAL; NEUROTOXIN; OXIDOPAMINE;

ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ENVIRONMENTAL FACTOR; FETUS; ISRAEL; NERVE CELL DEGENERATION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

EID: 0031558644     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(97)81717-9     Document Type: Article

References (18)

1. Burns R.S., Chiueh C.C., Markey S.P., Ebert M.H., Jacobowitz D.J., Kopin I.J. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. USA. 80:1983;4546-4550.
2. Fahn S. A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson's disease. Ann. Neurol. 32(Suppl.):1992;S128-S132.
3. 2+-channel blocker. Proc. Natl. Acad. Sci. USA. 90:1993;9523-9527.
4. Goldsmith J.R., Herishanu Y., Abarbanel J.M., Weinbaum Z. Clustering of Parkinson's disease points to environmental etiology. Arch. Environ. Health. 45:1990;88-94.
5. N. Grcevic, D. Jadro-Santel, S. Jukic, Cerebral changes in paraquat poisoning, in: L. Roizin, H. Shiraki, N. Grcevic (Eds.), Neurotoxicology, Raven Press, New York, 1977, pp. 468-484.
6. Hornykiewicz O. Lokalisation und das verhalten von noradrenalin und dopamin (3-hydroxytyramin) in der substantia nigra des normalen und Parkinson-Kranken menschen. Wien. Klin. Wochenschr. 73:1963;309-312.
7. Jenner P. Oxidative stress as a cause of Parkinson's disease. Acta Neurol. Scand. 84(Suppl. 136):1991;6-15.
8. W.C. Koller, in: W.C. Koller (Ed.), Handbook of Parkinson's Disease, Marcel Dekker, New York, 1987, pp. 51-80.
9. Logroscino G., Marder K., Cote L., Tang M.X., Shea S., Mayeux R. Dietary lipids and antioxidants in Parkinson's disease: a population-based, case-control study. Ann. Neurol. 39:1996;89-94.
10. Marshall J.F., Ungerstedt U. Supersensitivity to apomorphine following destruction of the ascending dopamine neurons: quantification using the rotational model. Eur. J. Pharmacol. 41:1977;361-367.
11. Niklas W.J., Vyas I., Heikkila R.E. Inhibition of NADH-linked oxidation in brain mitochondria 1-methyl-4-phenyl-1,2,3,6-phenylpyridine, a metabolite of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Life Sci. 36:1985;2503-2508.
12. Papke R.L., Craig A.G., Heinemann S.F. Inhibition of nicotinic acetylcholine receptors by bis(2,2,6,6-tetramethyl-4-piperidinyl)sebacate (Tinuvin 770), an additive to medical plastics. J. Pharmacol. Exp. Ther. 268:1994;718-726.
13. Parkinson's Study Group Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levadopa. Ann. Neurol. 39:1996;37-45.
14. Pospisil J., Nespurek S. Polym. Degrad. Stab. 49:1995;99-110.
15. Riederer P., Sofic E., Rausch W.D., Schmidt B., Reynolds G.P., Jellinger K., Youdim M.B. Transition metals, ferratin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52:1989;515-520.
16. Rose R.C., Bode A.M. Biology of free radical scavengers: an evaluation of ascorbate. FASEB J. 7:1993;1135-1142.
17. Tanner C.M. The role of environmental toxins in the etiology of Parkinson's disease. Trends Neurosci. 12:1989;49-54.
18. Tetrud J.W., Langston J.W. The effect of Deprenyl (Selegiline) on the natural history of Parkinson's disease. Science. 245:1989;519-522.